Holen Sie sich die Stockscreener-App
1.085
1.02%
-0.015
Schlusskurs vom Vortag:
$1.10
Offen:
$1.07
24-Stunden-Volumen:
4.31M
Relative Volume:
1.66
Marktkapitalisierung:
$127.69M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.3268
EPS:
-3.32
Netto-Cashflow:
$-175.17M
1W Leistung:
+40.93%
1M Leistung:
+24.32%
6M Leistung:
-47.65%
1J Leistung:
-45.29%
1-Tages-Spanne:
$1.01
$1.17
1-Wochen-Bereich:
$0.70
$1.17
52-Wochen-Spanne:
$0.6603
$3.70
Coherus Biosciences Inc Stock (CHRS) Company Profile
Firmenname
Coherus Biosciences Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Vergleichen Sie CHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CHRS | 1.0888 | 127.69M | 257.24M | -237.89M | -175.17M | -3.32 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.10 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.68 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-24 | Eingeleitet | Citigroup | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-03-28 | Hochstufung | UBS | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Neutral |
| 2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Eingeleitet | BofA Securities | Neutral |
| 2020-04-17 | Eingeleitet | SunTrust | Buy |
| 2019-08-13 | Eingeleitet | Mizuho | Buy |
| 2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-02 | Bestätigt | Maxim Group | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-09 | Bestätigt | Maxim Group | Buy |
| 2017-08-08 | Bestätigt | JP Morgan | Overweight |
| 2017-06-13 | Bestätigt | Maxim Group | Buy |
| 2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-09-07 | Eingeleitet | Maxim Group | Buy |
| 2016-07-27 | Eingeleitet | Citigroup | Buy |
| 2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Biosciences Inc Aktie (CHRS) Neueste Nachrichten
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Growth in Short Interest - MarketBeat
Los Angeles Capital Management LLC Has $967,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - MarketBeat
Coherus stock rallies 19% on Q3 earnings, Udenyca production update - MSN
Robert W. Baird Has Lowered Expectations for Coherus BioSciences (NASDAQ:CHRS) Stock Price - MarketBeat
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call Transcript - Insider Monkey
Coherus BioSciences' (CHRS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Supply Challenges - GuruFocus.com
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Coherus BioSciences Reports Strong Q3 2024 Growth - TipRanks
Coherus BioSciences earnings beat by $0.15, revenue topped estimates - Investing.com Canada
Coherus BioSciences: Q3 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30% - Simply Wall St
Coherus BioSciences Q3 2024 Earnings Preview - MSN
CHRS stock touches 52-week low at $0.71 amid market challenges - Investing.com Australia
Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to K - GuruFocus.com
Coherus BioSciences (CHRS) to Release Quarterly Earnings on Wednesday - MarketBeat
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire
Brokerages Set Coherus BioSciences, Inc. (NASDAQ:CHRS) Price Target at $7.13 - MarketBeat
CHRS stock plunges to 52-week low, hitting $0.79 By Investing.com - Investing.com Canada
CHRS stock plunges to 52-week low, hitting $0.79 - Investing.com India
Warning: CHRS is at high risk of performing badly - MSN
Such Is The Power Of Coherus Biosciences Inc (NASDAQ: CHRS) - Stocks Register
Exclusive-Russia to use ship-to-ship LNG loadings to free up ice-class tankers By Reuters - Investing.com
Coherus BioSciences (NASDAQ:CHRS) Lowered to "Hold" at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.85 amid market challenges - Investing.com India
CHRS stock touches 52-week low at $0.85 amid market challenges By Investing.com - Investing.com South Africa
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Increase in Short Interest - MarketBeat
How should investors view Coherus Biosciences Inc (CHRS)? - US Post News
Coherus Biosciences Inc Inc. (CHRS) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
StockNews.com Upgrades Coherus BioSciences (NASDAQ:CHRS) to “Buy” - Defense World
Financial Metrics Unveiled: Coherus Biosciences Inc (CHRS)’s Key Ratios in the Spotlight - The Dwinnex
AQR Capital Management LLC Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
719,999 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Acquired by AQR Capital Management LLC - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Upgraded at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus Biosciences Inc (CHRS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Finanzdaten der Coherus Biosciences Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):